Merrimack Pharmaceuticals Story Overview

MACK -- USA Stock  

USD 4.55  0.04  0.87%

Macroaxis does not monitor all media channels or aggregates social signals for Merrimack Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Merrimack Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Merrimack Pharmaceuticals. Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance.
Acquisition by John Mendelsohn of 7500 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Filed transaction by Merrimack Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3

Merrimack Pharmaceuticals Inc insider trading alert for grant of stock option (right to buy) by John Mendelsohn, the corporate stakeholder, on December 7, 2017. This event was filed by Merrimack Pharmaceuticals with SEC on 2017-09-15. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on December 7, 2017 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.95% . The trading delta at closing time when the story was published against the current closing price is 56.58% .

Similar stores for Merrimack Pharmaceuticals

a day ago at http://pressoracle.com 
Millennium Management LLC Boosts Holdings in Merrimack Pharmaceuticals Inc
news
PressOracleFull coverage
over two weeks ago at http://zeelandpress.com 
Merrimack Pharmaceuticals Inc Heading in the Right Direction
news
Zeeland PressFull coverage
over three weeks ago at http://cardinalweekly.com 
Procter Gamble Co Stock Sentiment
news
The Cardinal Weekly Full coverage
over a month ago at www.macroaxis.com 
Exercise or conversion by Edward Stewart of 5000 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Merrimack Pharmaceuticals officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at www.macroaxis.com 
Conversion by Michael Porter of 34286 shares of Merrimack Pharmaceuticals
Macroaxis News
Filed transaction by Merrimack Pharmaceuticals director. Derivative codes conversion of derivative security
over a month ago at http://www.analystsbuzz.com 
Cumberland Pharmaceuticals Inc. likely to attain 8.75 in 52-week period
news
Voice Of AnalystsFull coverage
over two months ago at http://endigest.com 
Newtyn Management Has Upped PgE Holding by 92.45 Million as Market Value Rose Trb Advisors LP Has ...
news
EN DigestFull coverage
over two months ago at http://www.thewellesleysnews.com 
Stock-research Ratings Merrimack Pharmaceuticals, Inc. , DMC Global Inc.
news
Analyst JournalFull coverage
over two months ago at http://pressoracle.com 
-0.04 Earnings Per Share Expected for Merrimack Pharmaceuticals Inc This Quarter
news
PressOracleFull coverage
over two months ago at http://ztribune.com 
Alecta Pensionsforsakring Omsesidigt Trimmed Rockwell Automation Position Monroe Capital Shorts ...
news
Z TribuneFull coverage
over three months ago at http://news.cmlviz.com 
Merrimack Pharmaceuticals Inc Risk Points versus Health Care
news
CML NewsFull coverage
over three months ago at www.macroaxis.com 
Conversion by Michael Porter of 28570 shares of Merrimack Pharmaceuticals
Macroaxis News
Filed transaction by Merrimack Pharmaceuticals director. Derivative codes conversion of derivative security
over six months ago at http://www.analystratings.com 
Fridays Midday Stock Update Titan Pharmaceuticals , RXi Pharmaceuticals Corp , Merrimack ...
news
Analyst RatingsFull coverage

Cash Flow from Operations

Cash Flow from Operations Comparative Analysis

  Cash Flow from Operations 
      Merrimack Pharmaceuticals Comparables 
Merrimack Pharmaceuticals is currently under evaluation in cash flow from operations category among related companies. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investor or analyst to check on the quality of a company earnings.

Peers

Merrimack Pharmaceuticals Related Equities

DOVA  7.15   
0%
100.0%
DNLI  3.32   
0%
46.0%
DRNA  3.12   
0%
43.0%
DVAX  1.66   
0%
23.0%
EQ  0.69   
0%
9.0%
CO  0.15   
0%
2.0%
ECYT  0.21   
2.0%
0%
NK  0.45   
6.0%
0%
EARS  1.54   
21.0%
0%
DMPI  1.61   
22.0%
0%
Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance. Please also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Search macroaxis.com